The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy
Abstract
The HER-2/neu oncogene encodes a transmembrane tyrosine kinase receptor with extensive homology to the epidermal growth factor receptor. HER-2/neu has been widely studied in breast cancer. In this review, the association of HER-2/neu gene and protein abnormalities studied by Southern and slot blotting, immunohistochemistry, enzyme immunoassays, and fluorescence in situ hybridization with prognosis in breast cancer is studied in depth by review of a series of 47 published studies encompassing more than 15,000 patients. The relative advantages of gene amplification assays and frozen/fresh tissue immunohistochemistry over paraffin section immunohistochemistry are discussed. The significance of HER-2/neu overexpression in ductal carcinoma in situ and the HER-2/neu status in uncommon female breast conditions and male breast cancer are also considered. The potential value of HER-2/neu status for the prediction of response to therapy in breast cancer is presented in the light of a series of recently published studies showing a range of impact on the outcome of patients treated with hormonal, cytotoxic, and radiation therapies. The evidence that HER-2/neu gene and protein abnormalities in breast cancer predict resistance to tamoxifen therapy and relative sensitivity to chemotherapy regimens including adriamycin is presented. The review will also evaluate the status of serum-based testing for circulating the HER-2/neu receptor protein and its ability to predict disease outcome and therapy response. In the final section, the review will briefly present preliminary data concerning the use of antibody-based therapies directed against the HER-2/neu protein and their potential to become a new modality for breast cancer treatment. The recently presented phase III clinical trial evidence that systemic administration of anti-HER2 antibodies (Herceptin), alone and in combination with cytotoxic chemotherapy in patients with HER-2/neu overexpressing primary tumors, can increase the time to recurrence and overall response rates in metastatic breast cancer is reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Prognostic and predictive factors in breast cancer by immunohistochemical analysis.
Allred, D. C., Harvey, J. M., Berardo, M. D., & Gm, C. (1998) · PubMed · Cited by 2,143
Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.737 · Cited by 1,380
c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer
Muss, H. B., Thor, A. D., Berry, D. A., Kute, T., Liu, E. T., Koerner, F., Cirrincione, C. T., Budman, D. R., Wood, W. C., Barcos, M., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405053301802 · Cited by 961
Neu-Protein Overexpression in Breast Cancer
van de Vijver, M. J., Peterse, J. L., Mooi, W. J., Wisman, P., Lomans, J., Dalesio, O., & Nusse, R. (1988) · New England Journal of Medicine · doi:10.1056/nejm198811103191902 · Cited by 860
Gusterson, B. A., Gelber, R. D., Goldhirsch, A., Price, K. N., Säve-Söderborgh, J., Anbazhagan, R., Styles, J., Rudenstam, C. M., Golouh, R., & Reed, R. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1049 · Cited by 838
Press, M. F., Bernstein, L., Thomas, P. A., Meisner, L. F., Zhou, J. Y., Ma, Y., Hung, G., Robinson, R. A., Harris, C., El-Naggar, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.8.2894 · Cited by 802
Self-citationPaik, S., Hazan, R., Fisher, E. R., Sass, R. E., Fisher, B., Redmond, C., Schlessinger, J., Lippman, M. E., & King, C. R. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.1.103 · Cited by 594
Berger, M. S., Locher, G. W., Saurer, S., Gullick, W. J., Waterfield, M. D., Groner, B., & Hynes, N. E. (1988) · PubMed · Cited by 565
(1996) · PubMed · Cited by 554
Seshadri, R., Firgaira, F. A., Horsfall, D. J., McCaul, K., Setlur, V, & Kitchen, P. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.1936 · Cited by 528
Press, M. F., Hung, G., Godolphin, W. J., & Slamon, D. (1994) · PubMed · Cited by 478
HER-2/neu amplification predicts poor survival in node-positive breast cancer.
Borg, Å., Tandon, A., Sigurdsson, H., Clark, G. M., Fernö, M., Fuqua, S. A. W., Killander, D., & Wl, M. (1990) · PubMed · Cited by 457
Allred, D. C., Clark, G. M., Tandon, A. K., Molina, R., Tormey, D. C., Osborne, C. K., Gilchrist, K. W., Mansour, E. G., Abeloff, M., & Eudey, L. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.4.599 · Cited by 456
Press, M. F., Pike, M. C., Chazin, V. R., Hung, G., Udove, J. A., Markowicz, M., Danyluk, J., Godolphin, W. J., Sliwkowski, M. X., & Akita, R. W. (1993) · PubMed · Cited by 426
Carlomagno, C., Perrone, F., Gallo, C., De Laurentiis, M., Lauria, R., Morabito, A., Pettinato, G., Panico, L., D'Antonio, A., Bianco, A. R., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2702 · Cited by 407
Wright, C., Nicholson, S., Angus, B., Sainsbury, J., Farndon, J., Cairns, J., Harris, A., & Horne, C. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.22 · Cited by 379
Slamon, D. J. (1998) · Medical Entomology and Zoology · Cited by 347
Kallioniemi, O., Holli, K., Visakorpi, T., Koivula, T., Helin, H. H., & Isola, J. J. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910490504 · Cited by 346
Pegram, M. D., Finn, R. S., Arzoo, K., Beryt, M., Pietras, R. J., & Slamon, D. J. (1997) · Oncogene · doi:10.1038/sj.onc.1201222 · Cited by 332
Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up.
Toikkanen, S., Helin, H., Isola, J., & Joensuu, H. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1044 · Cited by 313
Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic
Shepard, H. M., Lewis, G. D., Sarup, J. C., Fendly, B. M., Maneval, D., Mordenti, J., Figari, I., Kotts, C. E., Palladino, M. A., Ullrich, A., et al. (1991) · Journal of Clinical Immunology · doi:10.1007/bf00918679 · Cited by 294
Paterson, M. C., Dietrich, K. D., Danyluk, J., Paterson, A. H., LEES, A. W., Jamil, N. S. M., Hanson, J., Jenkins, H., Krause, B. E., & McBlain, W. A. (1991) · PubMed · Cited by 264
Follow-up study of HER-2/neu amplification in primary breast cancer.
Clark, G. M., & McGuire, W. L. (1991) · PubMed · Cited by 261
Rilke, F., Colnaghi, M. I., Cascinelli, N., Andreola, S., Baldini, M. T., Bufalino, R., Porta, G. D., Ménard, S., Pierotti, M. A., & Testori, A. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910490109 · Cited by 259
Yamauchi, H., O'Neill, A., Gelman, R., Carney, W., Tenney, D. Y., Hösch, S., & Hayes, D. F. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.7.2518 · Cited by 239
c-erbB-2 oncoprotein expression in primary and advanced breast cancer
Lovekin, C., Ellis, I., Locker, A., Robertson, J., Bell, J., Nicholson, R., Gullick, W., Elston, C., & Blamey, R. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.101 · Cited by 237
Amplification of c-erb B-2 and Aggressive Human Breast Tumors?
Ali, I. U., Campbell, G., Lidereau, R., & Callahan, R. (1988) · Science · doi:10.1126/science.3289120 · Cited by 236
Brossart, P., Stuhler, G., Flad, T., Stevanović, S., Rammensee, H., Kanz, L., & Brugger, W. (1998) · PubMed · Cited by 223
Male breast carcinoma: An evaluation of prognostic factors contributing to a poorer outcome
Joshi, M., Lee, A. K. C., Loda, M. F., Camus, M. G., Pedersen, C. A., Heatley, G. J., & Hughes, K. S. (1996) · Cancer · Cited by 221
Yu, D., Liu, B., Tan, M., Li, J., Wang, S., & Hung, M. (1996) · PubMed · Cited by 220
Têtu, B., & Brisson, J. (1994) · Cancer · Cited by 203
van Diest, P. J., van Dam, P., Henzen-Logmans, S. C., Berns, E., van der Burg, M. E., Green, J., & Vergote, I. (1997) · Journal of Clinical Pathology · doi:10.1136/jcp.50.10.801 · Cited by 196
Newby, J. C., Johnston, S. R. D., Smith, I. E., et al. (1997) · PubMed · Cited by 192
Prognosis and Breast Cancer: Recognition of Lethal and Favorable Prognostic Types
Page, D. L. (1991) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199104000-00002 · Cited by 189
Valone, F. H., Kaufman, P. A., Guyre, P. M., Lewis, L. D., Memoli, V, Deo, Y., Graziano, R., Fisher, J. L., Meyer, L., & Mrozek-Orlowski, M. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.9.2281 · Cited by 180
Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment
Berns, E. M. J. J., Foekens, J. A., van Staveren, I. L., van Putten, W. L. J., de Koning, H. Y. W. C. M., Portengen, H., & Klijn, J. G. M. (1995) · Gene · doi:10.1016/0378-1119(94)00534-y · Cited by 173
Zhang, L., Chang, C., Bacus, S. S., & Hung, M. (1995) · PubMed · Cited by 162
Archer, S., Eliopoulos, A., Spandidos, D., Barnes, D., Ellis, I., Blamey, R., Nicholson, R., & Robertson, J. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.497 · Cited by 159
HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications.
Baselga, J. M., Seidman, A. D., Rosen, P. P., & Norton, L. (1997) · PubMed · Cited by 157
Tsuda, H., Hirohashi, S., Shimosato, Y., Hirota, T., Tsugane, S., Watanabe, S., Terada, M., & Yamamoto, H. (1990) · Cancer · Cited by 151
The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer
O'Reilly, S., Barnes, D. M., Camplejohn, R., Bártková, J., Gregory, W. M., & Richards, M. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.102 · Cited by 130
Lodato, R. F., Maguire, H. C., Jr., Greene, M. I., et al. (1990) · PubMed · Cited by 122
Stockmeyer, B., Valerius, T., Repp, R., Heijnen, I., Bühring, H. ‐., Deo, Y. M., Kalden, J. R., Gramatzki, M., & van de Winkel, J. G. J. (1997) · PubMed · Cited by 94
Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody
Witters, L. M., Kumar, R., Chinchilli, V. M., et al. (1997) · Breast Cancer Research and Treatment · doi:10.1023/a:1005798224288 · Cited by 92
Giai, M., Roagna, R., Ponzone, R., Bortoli, M. D., Dati, C., & Sismondi, P. (1994) · PubMed · Cited by 89
Odagiri, E., Kanda, N., Jibiki, K., Demura, R., Aikawa, E., & Demura, H. (1994) · Cancer · doi:10.1002/1097-0142(19940615)73:12<2978::aid-cncr2820731215>3.0.co;2-5 · Cited by 79
Mack, L. A., Kerkvliet, N. I., Doig, G. S., & O’Malley, F. P. (1997) · Human Pathology · doi:10.1016/s0046-8177(97)90014-9 · Cited by 77
Overview of the Biologic Markers of Breast Cancer
Porter-Jordan, K., & Lippman, M. E. (1994) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(18)30188-6 · Cited by 76
The neu-oncogene: More than a prognostic indicator?
Potter, C. R. D. (1994) · Human Pathology · doi:10.1016/0046-8177(94)90083-3 · Cited by 73
Lupu, R., Cardillo, M., Harris, L. N., Hijazi, M., & Rosenberg, K. E. (1995) · Seminars in Cancer Biology · doi:10.1006/scbi.1995.0016 · Cited by 65
Sauter, G., Feichter, G. E., Torhorst, J. K. H., Moch, H., Novotná, H., Wagner, U., Dürmüller, U., & Waldman, F. M. (1996) · Acta Cytologica · doi:10.1159/000333683 · Cited by 55
Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression.
Jacquemier, J. D., Penault-Llorca, F. M., Viens, P., Houvenaeghel, G. F., Hassoun, J., Torrente, M., Adélaı̈de, J., & Birnbaum, D. (1994) · PubMed · Cited by 44
Charpin, C., Garcia, S., Bouvier, C., Martini, F., Lavaut, M.-N., Allasia, C., Bonnier, P., & Andrac, L. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.283 · Cited by 36
Potter, C. R. D., Schelfhout, A., Verbeeck, P., Lakhani, S. R., Brünken, R., Schroeter, C. A., van den Tweel, J. G., Schauer, A., & Sloane, J. P. (1995) · Human Pathology · doi:10.1016/0046-8177(95)90163-9 · Cited by 35
Inhibition of erbB-2-Positive Breast Cancer Cell Growth by erbB-2 Antisense Oligonucleotides
LIU, X., & Pogo, B. G. T. (1996) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1996.6.9 · Cited by 28
C-erbB-2 protein and neuroendocrine expression in intraductal carcinomas of the breast.
Lilleng, R., Hagmar, B., & Jm, N. (1992) · PubMed · Cited by 17
Cited by
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Wu, X., Liu, H., Liu, J., Haley, K. N., Treadway, J. A., Larson, J. P., Ge, N., Peale, F., & Bruchez, M. P. (2003) · Nature Biotechnology · doi:10.1038/nbt764 · Cited by 2,506
Non-coding RNA networks in cancer
Anastasiadou, E., Jacob, L. S., & Slack, F. J. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.99 · Cited by 1,884
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
Franklin, M. C., Carey, K. D., Vajdos, F. F., Leahy, D. J., de Vos, A. M., & Sliwkowski, M. X. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00083-2 · Cited by 1,120
An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors
Burgess, A. W., Cho, H.-S., Eigenbrot, C., Ferguson, K. M., Garrett, T. P. J., Leahy, D. J., Lemmon, M. A., Sliwkowski, M. X., Ward, C. W., & Yokoyama, S. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00350-2 · Cited by 909
Metadata
- Authors
- Ross, J. S., & Fletcher, J. A.
- Venue
- STEM CELLS
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-11
- Volume
- 16
- Issue
- 6
- Pages
- 413-428
- ISSN
- 1066-5099 (ISSN-L)
- 1549-4918
- OpenAlex
- W2161428561
- Cited by
- 985
- References
- 57
- FWCI
- 15.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.